title: RSV vaccine use--the missing data.
abstract: Respiratory syncytial virus (RSV) infection is the most important cause of hospitalization in infants and is one of the leading global causes of infant mortality and as such its prevention through vaccination is a public health priority. While essential for the successful implementation of vaccine programs, there remains a paucity of data on the epidemiology of the virus in different settings and age groups and limited knowledge about virus transmission and the health-care costs of the disease. Such data are now needed to populate health economic models and to inform optimal approaches to disease control through vaccination.
authors.affiliation: a Oxford Vaccine Group, Department of Paediatrics , University of Oxford , Oxford , UK.|b NIHR Oxford Biomedical Research Centre, Level 2 , Children's Hospital , Oxford , UK.
authors.forename: Simon B
authors.initials: SB
authors.lastname: Drysdale
authors.affiliation: a Oxford Vaccine Group, Department of Paediatrics , University of Oxford , Oxford , UK.
authors.forename: Charles J
authors.initials: CJ
authors.lastname: Sande
authors.affiliation: a Oxford Vaccine Group, Department of Paediatrics , University of Oxford , Oxford , UK.
authors.forename: Christopher A
authors.initials: CA
authors.lastname: Green
authors.affiliation: a Oxford Vaccine Group, Department of Paediatrics , University of Oxford , Oxford , UK.|b NIHR Oxford Biomedical Research Centre, Level 2 , Children's Hospital , Oxford , UK.
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Pollard
mesh_terms: D003365:Costs and Cost Analysis; D018562:Disease Transmission, Infectious / Q000517:prevention & control*; D006801:Humans; D007223:Infant; D018357:Respiratory Syncytial Virus Infections / Q000191:economics / Q000453:epidemiology* / Q000517:prevention & control*; D022261:Respiratory Syncytial Virus Vaccines / Q000008:administration & dosage* / Q000191:economics / Q000276:immunology*
chemical_list: D022261:Respiratory Syncytial Virus Vaccines
keywords: RSV; cost–effectiveness mode; epidemiology; health economics; respiratory syncytial virus; vaccine; viral transmission